Bee Venom Membrane-Active Peptide
Melittin is a bee venom peptide that disrupts cell membranes with exceptional potency, killing drug-resistant bacteria, disabling the lipid envelopes of viruses including HIV, and triggering apoptosis in cancer cell lines at low concentrations. People who are allergic to bee venom should not use this.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
15 mg
Format
Injectable
Composition
5 mg/ml per ml
Melittin inserts into phospholipid bilayers, forming toroidal pores and causing rapid membrane depolarisation and lysis. In cancer research, it activates apoptotic pathways (caspase-3/9 activation, cytochrome c release), inhibits NF-κB and MAPK signalling, and demonstrates anti-angiogenic effects by reducing VEGF expression. Its antimicrobial activity operates through the same membrane-disruption mechanism, active against gram-positive and gram-negative bacteria, enveloped viruses (including HIV and HCV), and drug-resistant pathogens. Targeted nanoparticle conjugates are under active investigation for tumour-selective delivery.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Melittin's membrane-disruption mechanism is effective against a wide range of pathogens including MRSA, VRE, and drug-resistant gram-negative bacteria: mechanisms that bypass conventional antibiotic resistance.
Multiple in vitro studies show melittin induces apoptosis in breast, prostate, lung, and liver cancer cell lines. Targeted nanoparticle conjugates represent the leading edge of research application.
Melittin disrupts the lipid envelope of enveloped viruses (HIV, HCV, HSV) making it an active subject of antiviral research independent of its cancer applications.
Explore selected publications on Melittin, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Evidence synthesis
Melittin nanomedicine review
Publication and key finding
Reviewing more than 100 papers, the authors describe preclinical anticancer activity for Melittin nanocarriers across multiple tumour models, alongside delivery strategies intended to reduce off-target and haemolytic effects.
Pharmaceutics
Evidence type
Preclinical study
Melittin breast-cancer cell and preclinical evidence
Publication and key finding
Melittin disrupted EGFR and HER2 activation in breast-cancer cells, and its addition enhanced docetaxel-associated tumour suppression in a mouse allograft model.
NPJ precision oncology
Evidence type
Preclinical study
Melittin antimicrobial cell and preclinical evidence
Publication and key finding
Melittin showed antibacterial activity against MRSA in laboratory testing and improved survival or wound recovery in two MRSA-infected mouse models.
Molecular medicine reports
Evidence type
Laboratory study
Melittin nanoparticle antiviral evidence
Publication and key finding
Melittin-loaded nanoparticles reduced infectivity of two HIV-1 strains in cell assays while preserving the viability of the vaginal epithelial cells tested.
Antiviral therapy
Evidence type
Preclinical study
Melittin nanoparticle tumour-model evidence
Publication and key finding
MnO2-Melittin nanoparticles produced stronger immune activation and greater inhibition of tumour growth and lung metastasis than either component alone across several mouse tumour models.
Biomaterials
Combinations used in research protocols where Melittin complements other compounds.
Melittin (nanoparticle conjugate) + Tumour-targeting ligands
Active research direction: melittin payload attached to tumour-specific receptor ligands for targeted cytotoxicity with reduced systemic toxicity.
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Allergy warning: Melittin is the principal peptide component of bee venom and has bee-venom-like activity. It must not be used by people with a known or suspected bee-venom allergy because exposure may cause a severe allergic reaction, including anaphylactic shock. Research evaluation and appropriate professional safeguards are required.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
